However, some patients respond poorly or generate resistance due to a shortage of PD‐L1 expression and dysfunctional immune response within the tumor microenvironment (TME).[2, 3] Moreover, similar to other traditional therapies (e.g., chemotherapy or radiotherapy), the accompanying side effects, such as immune‐related adverse effects (irAEs), also limit the clinical outcomes of immunotherapy. The gene discussed is CD274; the disease is neoplasm.